Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 226

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study

Open access
Ben‐Ami, Eytan, Barysauskas, Constance M., Solomon, Sarah, Tahlil, Kadija, Malley, Rita, Hohos, Melissa, Polson, Kathleen, Loucks, Margaret, Severgnini, Mariano, Patel, Tara, Cunningham, Amy, Rodig, Scott J., Hodi, F. Stephen, Morgan, Jeffrey A., Merriam, Priscilla, Wagner, Andrew J., Shapiro, Geoffrey I., George, Suzanne·2017·Cancer

Abstract

BACKGROUND: Immunotherapy has changed the therapeutic landscape in oncology. Advanced uterine leiomyosarcoma (ULMS) remains an incurable disease in most cases, and despite new drug approvals, improvements in overall survival have been modest at best. The goal of this study was to evaluate programmed‐death 1 (PD‐1) inhibition with nivolumab in this patient population. METHODS: This single‐center phase 2 trial completed enrollment between May and October 2015. Patients received 3 mg/kg of intravenous nivolumab on day 1 of each 2‐week cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate. We assessed PD‐1, PD‐ligand 1 (PD‐L1), and PD‐L2 expression in archival tumor samples and variations in immune‐phenotyping of circulating immune cells during treatment. RESULTS: Twelve patients were enrolled in the first stage of the 2‐stage design. A median of 5 (range, 2‐6) 2‐week cycles of nivolumab were administered. Of the 12 patients, none responded to treatment. The overall median progression‐free survival was 1.8 months (95% confidence interval, 0.8‐unknown). The study did not open the second stage due to lack of benefit as defined by the statistical plan. Archival samples were available for 83% of patients. PD‐1 (>3% of cells), PD‐L1, and PD‐L2 (>5% and >10% of tumor cells, respectively) expression were observed in 20%, 20%, and 90% of samples, respectively. No significant differences were observed between pre‐ and posttreatment cell phenotypes. CONCLUSION: Single‐agent nivolumab did not demonstrate a benefit in this cohort of previously treated advanced ULMS patients. Further biomarker‐driven approaches and studies evaluating combined immune checkpoint‐modulators should be considered. Cancer 2017;123:3285‐90. © 2017 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.30738

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 226

Metadata

Authors
Ben‐Ami, E., Barysauskas, C. M., Solomon, S., Tahlil, K., Malley, R., Hohos, M., Polson, K., Loucks, M., Severgnini, M., Patel, T., Cunningham, A., Rodig, S. J., Hodi, F. S., Morgan, J. A., Merriam, P., Wagner, A. J., Shapiro, G. I., & George, S.
Venue
Cancer
Publisher
Wiley
Published
2017-04-25
Volume
123
Issue
17
Pages
3285-3290
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2610035536
Cited by
226
References
10
FWCI
9.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. https://app.cochat.ai/papers/10.1002/cncr.30738
The paper
Ben‐Ami, E., Barysauskas, C. M., Solomon, S., Tahlil, K., Malley, R., Hohos, M., Polson, K., Loucks, M., Severgnini, M., Patel, T., Cunningham, A., Rodig, S. J., Hodi, F. S., Morgan, J. A., Merriam, P., Wagner, A. J., Shapiro, G. I., & George, S. (2017). Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. Cancer. https://doi.org/10.1002/cncr.30738

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.